pixelized colorful circle

Antibody Design and Engineering for Preclinical Research

Request Access

ConvergeAB™ is an AI-driven molecule design platform for antibody molecule design and optimization. From computational molecule design and design molecule ideation to affinity maturation, it supports candidate selection, lead optimization, and de novo generation across IgG, VHH, scFv, and bispecific formats. Using generative and predictive models to explore broad sequence space, it ranks candidates by binding, developability, and structural fit, accelerating confident decisions from hit to lead.

ConvergeAB™ is an AI-driven molecule design platform for antibody molecule design and optimization. From computational molecule design and design molecule ideation to affinity maturation, it supports candidate selection, lead optimization, and de novo generation across IgG, VHH, scFv, and bispecific formats. Using generative and predictive models to explore broad sequence space, it ranks candidates by binding, developability, and structural fit, accelerating confident decisions from hit to lead.

Speed

Accelerate antibody discovery with Gen AI-powered design and ranking of candidates, significantly shortening timelines by replacing slow, iterative lab work with rapid, guided predictions.

Speed

Accelerate antibody discovery with Gen AI-powered design and ranking of candidates, significantly shortening timelines by replacing slow, iterative lab work with rapid, guided predictions.

Cost

Eliminate costly trial-and-error by rapidly identifying optimal antibody candidates early. Avoid expensive screening cycles and reduce dependence on animal experiments to significantly lower discovery costs.

Cost

Eliminate costly trial-and-error by rapidly identifying optimal antibody candidates early. Avoid expensive screening cycles and reduce dependence on animal experiments to significantly lower discovery costs.

Precision

Engineer antibodies for specificity and developability by integrating epitope, manufacturability and immunogenicity constraints from the start. Reduce risk with optimization of structural and functional fit.

Precision

Engineer antibodies for specificity and developability by integrating epitope, manufacturability and immunogenicity constraints from the start. Reduce risk with optimization of structural and functional fit.

Generate

Predict

Explain

Predict binding & developability

Generate

Predict

Explain

Predict binding

01

01

Generate diverse antibody candidates in silico

Optimized antibody candidates, generated with unprecedented speed and precision through AI-driven molecule design. Define your target and optional constraints, and ConvergeAB uses computational molecule design and affinity maturation to design molecule variants, rapidly producing diverse sequences ranked for binding affinity, structural stability, and functional relevance.

Optimized antibody candidates, generated with unprecedented speed and precision through AI-driven molecule design. Define your target and optional constraints, and ConvergeAB uses computational molecule design and affinity maturation to design molecule variants, rapidly producing diverse sequences ranked for binding affinity, structural stability, and functional relevance.

Start generating

02

02

Better leads,
fewer cycles

Optimize affinity, stability, solubility, immunogenicity, and expression in a single AI-driven molecule design pass. Each lead is derived from millions of in silico designs, ranked and filtered to maximize success and cut lab iterations.

Optimize affinity, stability, solubility, immunogenicity, and expression in a single AI-driven molecule design pass. Each lead is derived from millions of in silico designs, ranked and filtered to maximize success and cut lab iterations.

Start optimizing

03

03

Prioritize high-performing candidates before entering the lab

ConvergeAB screens millions of antibody sequences per target using AI-driven molecule design, scoring each for affinity, developability, epitope specificity, humanization, and structural fit. Clear scores and visual outputs enable confident selection, accelerating discovery and reducing experimental burden.

ConvergeAB screens millions of antibody sequences per target using AI-driven molecule design, scoring each for affinity, developability, epitope specificity, humanization, and structural fit. Clear scores and visual outputs enable confident selection, accelerating discovery and reducing experimental burden.

Start screening

04

04

Generate, optimize and screen - all in one single platform

Each candidate includes rich predictive profiles - affinity, stability, solubility, immunogenicity, and docking-based structural fit - powered by AI-driven molecule design. Review key metrics, explore 3D visualizations, and export top sequences for synthesis, whether you validate in-house or with a CRO, moving forward with confidence and clarity.

Each candidate includes rich predictive profiles - affinity, stability, solubility, immunogenicity, and docking-based structural fit - powered by AI-driven molecule design. Review key metrics, explore 3D visualizations, and export top sequences for synthesis, whether you validate in-house or with a CRO, moving forward with confidence and clarity.

Start designing

"With ConvergeAB, your data and sequences remain fully private and under your control. Each deployment is provisioned as a dedicated, isolated instance, ensuring that your data is never shared, exposed or used outside your organization. All outputs are exclusively yours, with full ownership and IP retained at every stage."

Dov Gertz

|

CEO & Co-Founder

Private by design

Only your team can access your data. We don’t share, reuse, or train on it. Your privacy is always protected.

Complete ownership

All sequences and outputs belong to you, with no royalties or restrictions. You have full rights and control.

Fully managed

We handle infrastructure end-to-end, from setup to scaling, so your team can focus entirely on the science.

Expert support

Our scientists and AI experts guide you through every stage, ensuring smooth design and discovery.

How it works

How it works

ConvergeAB™ is trained on over 1 trillion natural protein tokens, including 7 million antibody sequences, 3 million antibody–antigen pairs, and 10,000 developability measurements. This foundation enables affinity maturation, developability optimization, humanization, patent escape and IP expansion, and candidate screening across IgG, ScFv, and VHH (Beta) formats.

Input

Explainability & Output

A Classification Head links the patient representation to clinical outcomes. The model then extracts Disease-specific association scores and Cell-type-gene importance scores. This explainability allows us to extract the genes that are the main drivers for a specific disease or response.

Explainability & Output

A Classification Head links the patient representation to clinical outcomes. The model then extracts Disease-specific association scores and Cell-type-gene importance scores. This explainability allows us to extract the genes that are the main drivers for a specific disease or response.

2nd

Predictors

Explainability & Output

A Classification Head links the patient representation to clinical outcomes. The model then extracts Disease-specific association scores and Cell-type-gene importance scores. This explainability allows us to extract the genes that are the main drivers for a specific disease or response.

Explainability & Output

A Classification Head links the patient representation to clinical outcomes. The model then extracts Disease-specific association scores and Cell-type-gene importance scores. This explainability allows us to extract the genes that are the main drivers for a specific disease or response.

2nd

Output

Explainability & Output

A Classification Head links the patient representation to clinical outcomes. The model then extracts Disease-specific association scores and Cell-type-gene importance scores. This explainability allows us to extract the genes that are the main drivers for a specific disease or response.

Recent Updates

Resources Page

Case Study

Zero-Shot Design of a Biobetter Cetuximab: Enhancing EGFR Binding with ConvergeAB™

Case Study

Generating Clinic-Ready Antibodies: Benchmarking ConvergeAB™ Against Blockbuster Drugs

Blog

Solubility: The Quiet Deal-Breaker in Antibody Development

Recent Updates

Case Study

Zero-Shot Design of a Biobetter Cetuximab: Enhancing EGFR Binding with ConvergeAB™

Case Study

Generating Clinic-Ready Antibodies: Benchmarking ConvergeAB™ Against Blockbuster Drugs

Blog

Solubility: The Quiet Deal-Breaker in Antibody Development

Resources Page

pixelized colorful circle

Start designing
better antibodies

Access ConvergeAB

pixelized colorful circle

Start designing
better antibodies

Access ConvergeAB